DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Melanoma subtypes, Breslow depth and urgent referral

Essential points for quick revision.

Synopsis

Recognise major cutaneous melanoma subtypes, refer suspicious lesions urgently, preserve diagnostic architecture through full-thickness excision biopsy, and interpret Breslow depth as a central staging and management variable.

  • Superficial-spreading melanoma often evolves as an irregular multicoloured macule or plaque; nodular melanoma is elevated, firm and rapidly growing and may be uniformly coloured.
  • Lentigo maligna melanoma develops within a slowly enlarging irregular macule on chronically sun-damaged head or neck; invasion may arise after a prolonged in-situ phase.
  • Acral lentiginous melanoma affects palms, soles or nail units and must be considered in every skin tone; delayed recognition contributes to thicker presentation.

Key red flags

Rapid nodular growth, ulceration, spontaneous bleeding, acral or nail-unit evolution, palpable nodes, neurological or systemic metastatic symptoms, or a lesion scoring 3 or more on the weighted seven-point checklist requires urgent cancer-pathway assessment.

Nodular pattern

A firm elevated lesion grows continuously over weeks to months and may be black, brown, red or skin-coloured.

Investigation priorities

01
Specialist dermoscopyFirst step

Identify melanoma-specific pigment, vascular, acral and nail structures and choose the biopsy plan.

Management branches

Suspicious primary lesionRefer intact for diagnosis

Clinical or dermoscopic features, evolution, nodular growth or acral or nail change raises melanoma concern.

  1. Make an urgent suspected-cancer referral with precise site, size, evolution and risk information and suitable consented images if locally supported.
  2. Leave the lesion intact for specialist dermoscopy and complete full-thickness excision biopsy unless an agreed expert pathway directs otherwise.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom